| Literature DB >> 32648210 |
Cristina Díaz Del Arco1,2, Lourdes Estrada Muñoz3, Rodrigo Barderas Manchado4, Alberto Peláez García5, Luis Ortega Medina6,7, Elena Molina Roldán7, Guillermo Solís Fernández4, Soledad García Gómez de Las Heras3, Mª Jesús Fernández Aceñero6,8.
Abstract
Aryl hydrocarbon receptor (AHR) interacting protein (AIP) is a chaperone which binds to inactive AHR in the cell cytoplasm. AHR is best known for mediating the toxicity of halogenated aromatics, but it has also been linked to carcinogenesis and tumor progression in several tumor types. Our aims are to assess the features of AIP immunohistochemical (IHC) staining and to evaluate its possible role as a prognostic marker in gastric cancer (GC). Retrospective study of 147 cases of resected GC. Clinicopathological features were collected, tissue microarrays were constructed for AIP IHC and statistical analysis were performed. AIP staining was observed in 50.3% of tumors. All AIP-positive cases exhibited cytoplasmic or membranous staining, variably associated with nuclear co-staining. 93.2% of AIP-positive tumors showed AIP immunoreactivity in 100% of cells. Staining intensity was mild, moderate and intense in 33.8%, 13.5% and 52.7% of cases. Tumors were stratified according to AIP staining intensity into low expression (no or mild AIP immunoreactivity) and high expression (moderate or intense AIP immunoreactivity). 36.6% of our cases showed high AIP expression. High AIP expression was significantly and independently correlated to tumor progression and cancer death. Tumors with high AIP expression showed lower survival and higher progression rates. AIP expression might be useful for determining GC prognosis. More studies are needed to clarify the role of AHR pathway in GC, AIP expression and its potential use as a surrogate marker for selecting patients for AHR modulation therapy.Entities:
Keywords: AIP; Aryl hydrocarbon receptor interacting protein; Gastric cancer; Immunohistochemistry; Prognosis
Mesh:
Substances:
Year: 2020 PMID: 32648210 DOI: 10.1007/s12253-020-00863-7
Source DB: PubMed Journal: Pathol Oncol Res ISSN: 1219-4956 Impact factor: 3.201